 SAN FRANCISCO, May 20, 2021 PRNewswire -- Nektar Therapeutics Nasdaq: NKTR today announced the publication of preclinical data in the Journal of Translational Autoimmunity describing NKTR-358, a first-in-class, composition of stable PEG conjugates of native IL-2 designed to selectively stimulate T regulatory Treg cell function. NKTR-358 is currently in development for the treatment of a range of autoimmune and inflammatory disorders. 